Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 325 | 0.91 |
| pathways Reactome | 10 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8007
Sealed predictions
- GIT1 in dopamine neurons, braak-0.75 (p 0.020) → +0.10 (p 0.790)receipt 8014
Swarm cases
receipt 8014: GIT1 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.176, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.188, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.26 (p 0.294, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.24, sign flips 0; without severely affected donors -0.33 (p 0.176, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.62 (p 0.0057, n 18) vs -0.33 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GIT1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GIT1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.00 p 1.000 (needs p < 2.7e-4)
Receipts
loading the receipts